Format

Send to

Choose Destination
Am J Kidney Dis. 2015 May;65(5):728-36. doi: 10.1053/j.ajkd.2014.10.014. Epub 2014 Nov 4.

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Author information

1
Denver Nephrologists PC, Denver, CO. Electronic address: gablock@dnresearch.org.
2
Hofstra-North Shore LIJ School of Medicine, Great Neck, NY.
3
Nephrology Service, IMIBIC, Hospital Universitario, Cordoba, Spain.
4
Denver Nephrologists PC, Denver, CO.
5
Keryx Biopharmaceuticals Inc, New York, NY.
6
Renal Associates PA, San Antonio, TX.
7
Department of Medicine, Institute for Public Health and Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL.
8
Stanford University School of Medicine, Palo Alto, CA.

Abstract

BACKGROUND:

Iron deficiency anemia and serum phosphate levels > 4.0mg/dL are relatively common in chronic kidney disease stages 3 to 5 and are associated with higher risks of progressive loss of kidney function, cardiovascular events, and mortality.

STUDY DESIGN:

Double-blind, placebo-controlled, randomized trial.

SETTING & PARTICIPANTS:

149 patients with estimated glomerular filtration rates < 60 mL/min/1.73 m(2), iron deficiency anemia (hemoglobin, 9.0-12.0 g/dL; transferrin saturation [TSAT]≤ 30%, serum ferritin ≤ 300 ng/mL), and serum phosphate levels ≥ 4.0 to 6.0mg/dL. Use of intravenous iron or erythropoiesis-stimulating agents was prohibited.

INTERVENTION:

Randomization to treatment for 12 weeks with ferric citrate coordination complex (ferric citrate) or placebo.

OUTCOMES & MEASUREMENTS:

Coprimary end points were change in TSAT and serum phosphate level from baseline to end of study. Secondary outcomes included change from baseline to end of treatment in values for ferritin, hemoglobin, intact fibroblast growth factor 23 (FGF-23), urinary phosphate excretion, and estimated glomerular filtration rate.

RESULTS:

Ferric citrate treatment increased mean TSAT from 22% ± 7% (SD) to 32% ± 14% and reduced serum phosphate levels from 4.5 ± 0.6 to 3.9 ± 0.6 mg/dL, while placebo exerted no effect on TSAT (21% ± 8% to 20% ± 8%) and less effect on serum phosphate level (4.7 ± 0.6 to 4.4 ± 0.8 mg/dL; between-group P<0.001 for each). Ferric citrate increased hemoglobin levels (from 10.5 ± 0.8 to 11.0 ± 1.0 g/dL; P<0.001 vs placebo), reduced urinary phosphate excretion 39% (P<0.001 vs placebo), and reduced serum intact FGF-23 levels from a median of 159 (IQR, 102-289) to 105 (IQR, 65-187) pg/mL (P=0.02 vs placebo). The incidence and severity of adverse effects were similar between treatment arms.

LIMITATIONS:

The study is limited by relatively small sample size and short duration and by having biochemical rather than clinical outcomes.

CONCLUSIONS:

Short-term use of ferric citrate repletes iron stores, increases hemoglobin levels, and reduces levels of serum phosphate, urinary phosphate excretion, and FGF-23 in patients with chronic kidney disease stages 3 to 5.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01736397.

KEYWORDS:

Chronic kidney disease (CKD); ferric citrate coordination complex (ferric citrate); fibroblast growth factor 23 (FGF-23); hemoglobin; iron repletion; iron-deficiency anemia; oral iron therapy; phosphate binder; randomized controlled trial; serum phosphate; transferrin saturation (TSAT); urinary phosphate excretion

PMID:
25468387
DOI:
10.1053/j.ajkd.2014.10.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center